Axis Therapeutics is a leading cancer immunotherapy company focused on the development of T cell therapies.
The Company is developing a novel class of innovative TCR-T therapies designed to harness the immune system to recognize and destroy cancerous cells in more patients, more effectively.
Through the TCR-T technology platform, the Company has generated engineered T cells with higher binding affinity and specificity for a defined tumor antigen. Preliminary studies have shown positive clinical signals in subjects with multiple solid tumor types.
We believe our TCR-T platform will be able to target a broad range of solid tumors, and provide patients with potentially long term effective cancer control without the need for sustained supportive care.